iShares Neuroscience and Healthcare ETF (IBRN) Holdings
For informational purposes only. Not financial advice.
iShares Neuroscience and Healthcare ETF (IBRN) has a last stored price of $32.55, as of the Oct 2, 2026 trading session. It has a 0.47% expense ratio and $5M in assets under management.
Holdings and weights below are as of Mar 15, 2026. In the stored portfolio snapshot, the largest listed holding is Praxis Precision Medicines Inc Ordinary Shares (PRAX) at 5.61%, and the largest sector allocation is Healthcare at 100.0%.
iShares Neuroscience and Healthcare ETF (IBRN) ETF — Price, Holdings & Analysis
ETF Overview
Risk Metrics
- Beta: 1.20
Expense Ratio
What does IBRN hold?
This fund data is more than 45 days old; verify current holdings with the issuer.
How Is the Fund Allocated?
| Sector | Weight |
|---|---|
| Healthcare | 100.0% |
| Country | Weight |
|---|---|
| United States | 68.9% |
| Canada | 5.7% |
| Ireland | 4.5% |
| United Kingdom | 3.4% |
| Netherlands | 3.4% |
| Sweden | 2.9% |
| South Korea | 2.5% |
| Denmark | 2.1% |
| China | 1.8% |
| Japan | 1.7% |
Dividend Yield
- ARK Innovation ETF (ARKK) — 0.75% expense ratio
- Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
- State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
- State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
- State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio
- WisdomTree Emerging Markets ESG Fund (DVEM) — 0.32% expense ratio
- Goldman Sachs ActiveBeta Emerging Markets Equity ETF (GEM) — 0.59% expense ratio
- iShares MSCI EAFE ETF (EFA) — 0.32% expense ratio
- iShares iBoxx $ High Yield Corporate Bond ETF (HYG) (Fixed Income) — 0.49% expense ratio
- iShares 20+ Year Treasury Bond ETF (TLT) (Fixed Income) — 0.15% expense ratio
- iShares MSCI Emerging Markets ETF (EEM) (Equity) — 0.72% expense ratio
- iShares MSCI UAE ETF (UAE) (Equity) — 0.59% expense ratio
- iShares Climate Conscious & Transition MSCI USA ETF (USCL) (Equity) — 0.08% expense ratio
Questions & Answers
What is IBRN and what does it track?
The iShares Neuroscience and Healthcare ETF (IBRN) seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience.
This means the fund invests in companies involved in the research, development, and commercialization of treatments and technologies related to neurological disorders and brain health.
What is the expense ratio for IBRN?
The expense ratio for IBRN is 0.47%. This means that for every $10,000 invested in the fund, $47 is used to cover the fund's operating expenses annually.
While this is a cost to consider, it's important to weigh it against the potential benefits of the fund's targeted investment strategy. When compared to the average expense ratio for equity ETFs, IBRN's expense ratio is slightly higher.
What are the top holdings in IBRN?
The top holdings in IBRN, as of 2026-03-15, include Praxis Precision Medicines Inc (5.61%), Axsome Therapeutics Inc (4.53%), and Biogen Inc (4.36%). Alkermes PLC (4.21%) and Supernus Pharmaceuticals Inc (4.07%) also rank among the fund's largest allocations.
These companies represent a significant portion of IBRN's portfolio and reflect the fund's focus on neuroscience and healthcare innovation. These holdings are primarily in the pharmaceutical and biotechnology industries.
Is IBRN a good long-term investment?
Determining whether IBRN is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and time horizon. IBRN offers targeted exposure to the neuroscience and healthcare sector, which may present growth opportunities but also involves specific risks.
The fund's beta of 1.20 suggests higher volatility compared to the broader market.
How does IBRN compare to similar ETFs?
IBRN differentiates itself through its specific focus on neuroscience and healthcare innovation. While other healthcare ETFs may offer broader exposure to the healthcare sector, IBRN targets companies directly involved in neuroscience-related activities.
The fund's expense ratio of 0.47% is comparable to other specialized ETFs.
Does IBRN pay dividends?
As of 2026-03-15, IBRN has a dividend yield of 0.00%. This indicates that the fund does not currently distribute dividends to its shareholders. Investors seeking income-generating investments may want to consider other ETFs with a higher dividend yield.
The fund's focus is primarily on capital appreciation through investments in growth-oriented companies within the neuroscience and healthcare sector.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
Written by machine, not reviewed page by page. Editorial oversight is systemic: the rules and the sources are checked, individual pages are not.